Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Nektar Therapeutics, a developer of drug delivery technologies, has stopped efforts to find a partner for its inhaled insulin program after Pfizer, its former partner, released negative clinical results last week. An ongoing review of clinical data for the Pfizer product Exubera showed an increase in lung cancer cases among former smokers using inhaled insulin compared with a control group. Pfizer pulled Exubera from the market in October 2007 after 18 months of limited patient interest and dismal sales. To conclude their product development relationship, Pfizer paid Nektar $135 million and agreed to transfer product rights if Nektar found another partner.
This article has been sent to the following recipient: